Scott Requadt

Mr. Requadt has been a member of ESSA’s board since 2016 and is currently Chief Executive Officer of Talaris Therapeutics, Inc., a publicly held, late-stage cell therapy company. Mr. Requadt has over 20 years of operating and investment experience in the pharmaceutical industry. Previously, he was a Managing Director at Clarus (now Blackstone Life Sciences), where he sourced, lead and managed multiple investments for Clarus, spanning therapeutics to medtech and diagnostics. He previously served on the Boards of Edev S.a.r.l., Avrobio, VBI Vaccines and TyRx, Inc. Prior to joining Clarus in 2005, Scott was Director, Business Development of TransForm Pharmaceuticals, Inc until it was acquired by Johnson & Johnson. Prior to TransForm, Mr. Requadt was an M&A attorney at the NYC-based law firm of Davis Polk & Wardwell, where he represented numerous private equity, pharma and technology clients. Previously, Mr. Requadt was a law clerk for a senior judge at the Supreme Court of Canada.

Mr. Requadt holds a B.Com (Economics & Finance) from McGill University (First Class Honors), a LLB (JD) from the University of Toronto and an M.B.A. from Harvard Business School, where he was a Baker Scholar.